FibroGen Inc. (NASDAQ:FGEN) shares shot up 2.6% on Monday . The company traded as high as $19.95 and last traded at $19.63, with a volume of 146,432 shares. The stock had previously closed at $19.13.

A number of brokerages have weighed in on FGEN. Credit Suisse Group AG reissued a “buy” rating on shares of FibroGen in a research note on Wednesday, May 25th. Zacks Investment Research raised FibroGen from a “sell” rating to a “hold” rating in a research note on Tuesday, May 10th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. FibroGen has a consensus rating of “Buy” and a consensus price target of $33.50.

The stock’s market cap is $1.19 billion. The firm has a 50-day moving average of $17.07 and a 200 day moving average of $18.38.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.45) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.56) by $0.11. On average, equities research analysts predict that FibroGen Inc. will post ($1.02) earnings per share for the current fiscal year.

In other FibroGen news, CEO Thomas B. Neff sold 37,798 shares of FibroGen stock in a transaction that occurred on Wednesday, July 27th. The shares were sold at an average price of $18.38, for a total value of $694,727.24. Following the transaction, the chief executive officer now owns 3,413,255 shares in the company, valued at $62,735,626.90. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider K Peony Yu sold 2,344 shares of FibroGen stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $17.96, for a total transaction of $42,098.24. Following the completion of the transaction, the insider now owns 210,257 shares in the company, valued at approximately $3,776,215.72. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have bought and sold shares of the company. Cornerstone Capital Management Holdings LLC. acquired a new position in FibroGen during the fourth quarter valued at about $3,067,000. PNC Financial Services Group Inc. raised its position in FibroGen by 8,621.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 35,756 shares of the biopharmaceutical company’s stock valued at $1,090,000 after buying an additional 35,346 shares during the period. California Public Employees Retirement System acquired a new position in FibroGen during the fourth quarter valued at about $3,397,000. Rhumbline Advisers raised its position in FibroGen by 8.7% in the fourth quarter. Rhumbline Advisers now owns 45,940 shares of the biopharmaceutical company’s stock valued at $1,400,000 after buying an additional 3,675 shares during the period. Finally, Swiss National Bank raised its position in FibroGen by 1.8% in the fourth quarter. Swiss National Bank now owns 63,400 shares of the biopharmaceutical company’s stock valued at $1,932,000 after buying an additional 1,100 shares during the period.

FibroGen, Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.